Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 552 results for "mirati"

3 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

Form 3 - Initial statement of beneficial ownership of securities SEC Accession No. 0000899243-16-010974 Filing Date 2016-01-05 Accepted 2016-01-05 21:21:25 Documents 1 Period of Report 2016-01-04 Filing Date Changed 2016-01-05 Document Format Files ... SEC, 1 month ago

1 images for "mirati"

Ticker Report, 3 weeks ago
TheStreet.com

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib MGCD265 In Non Small Cell Lung Cancer NSCLC Trial

By a News Reporter-Staff News Editor at -- Guardant Health , the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati") ( NASDAQ : MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced ...
 Equities.com1 month ago Guardant Health, Mirati collaborate to develop ctDNA assay for glesatinib  PharmaBiz1 month ago OrbiMed Leads $100M Series D for Guardant Health  Citybizlist1 month ago Cancer Blood-Test Startup Guardant Raises Almost $100 Million  Bloomberg1 month ago
[x]  

Mirati Therapeutics Appoints Vice President, Investor Relations And Corporate Communications

SAN DIEGO , Jan. 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate Communications. As a seasoned communicator, Ms. Graham has ...
 BioSpace1 month ago Mirati Therapeutics Appoints Marcy Graham Vice President, Investor Relations and Corporate Communications  4 Traders1 month ago Mirati Therapeutics, Inc. Files SEC Form CORRESP, Correspondence (Nov. 16, 2015)  Equities.com1 month ago Mirati Therapeutics : Initiates Glesatinib MGCD265 Phase 2 Trial In Non-Small Cell Lung Cancer NSCLC  4 Traders1 month ago
[x]  
Odisha Samaya

PM Modi, Sonia wish Prez Mukherjee on his birthday

n of humble origins, Mukherjee was born on Dec 11, 1935 in West Bengal's Mirati village in a freedom fighters' family IANS | New Delhi December 11, 2015 Last Updated at 11:50 IST PM Narendra Modi called on President Mukherjee at Rashtrapati Bhavan on first ...
 Business Standard1 month ago Kejriwal wishes President on birthday  Business Standard1 month ago PM Modi tweets birthday wishes to President Mukherjee  Odisha Samaya1 month ago President Mukherjee 'invaluable asset' of nation: Modi  Times of India1 month ago
[x]  
TheStreet.com

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib MGCD265 In Non-Small Cell Lung Cancer NSCLC

By a News Reporter-Staff News Editor at Cancer Weekly -- Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced ...
 4 Traders1 month ago Foundation Medicine, Inc. And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)  BioSpace1 month ago FOUNDATION MEDICINE : And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)  4 Traders1 month ago
[x]  

Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference

Article Rating: December 31, 1969 07:00 PM EST Latest Stories By Elizabeth White Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect ...
 Sys-Con Media2 months ago
[x]  
Ticker Report

Mirati Therapeutics Inc (MRTX) Hits New 52-week Low During February 03 Session

Mirati Therapeutics Inc ( MRTX ) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $21.02, Mirati Therapeutics Inc dropped to $19.69 for a new 52-week low. By the closing bell, the company's stock ...
 Equities.com4 days ago Mirati Therapeutics, Inc. (NASDAQ:MRTX) Receives Consensus Rating of Buy from Analysts  Ticker Report6 days ago Mirati Therapeutics Inc (MRTX) Drops 10.11% on January 27  Equities.com1 week ago Zacks: Analysts Expect Mirati Therapeutics, Inc. (NASDAQ:MRTX) to Post -$0.95 Earnings Per Share  SleekMoney1 week ago
[x]  

Commit To Buy Mirati Therapeutics At $17.50, Earn 13.4% Annualized Using Options

at 11:56 AM EST Investors considering a purchase of Mirati Therapeutics Inc (MRTX) stock, but cautious about paying the going market price of $23.88/share, might benefit from considering selling puts among the alternative strategies at their ...
 Minyanville1 week ago
[x]  

Boulegeris Investments Inc. Sells 8,865 Shares of Mirati Therapeutics, Inc. (MRTX)

Boulegeris Investments Inc. lowered its stake in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 48.6% during the fourth quarter, according to its most recent disclosure with the SEC. The hedge fund owned 9,375 shares of the company's stock ...
 Ticker Report2 weeks ago Large Outflow of Money Witnessed in Mirati Therapeutics, Inc.  MoneyFlowIndex.org1 month ago

Oversold Conditions For Mirati Therapeutics

January 19, 2016 at 16:25 PM EST Oversold Conditions For Mirati Therapeutics Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of ...
 Marketplace2 weeks ago Mirati Therapeutics Enters Oversold Territory (MRTX)  Market Pulse Navigator1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less